NGM Biopharmaceuticals Gets $50M For Diabetes, Obesity Treatments

South San Francisco-based NGM Biopharmaceuticals said last week that it has raised $50M in a Series C funding round, to go towards its development of therapeutics for the treatment of diabetes, obesity and other cardio‐metabolic diseases. The funding included the Topspin Fund, as well as existing investors The Column Group, Prospect Venture Partners, Rho Ventures and Tichenor Ventures. The firm said it has now raised over $130M for the company. More information »